Dongsheng Yue

Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial

Dongsheng Yue, Shidong Xu, Qun Wang et al. · The Lancet Respiratory Medicine · 2018 · 293 citations

Medicine, Oncology, Pharmacology +13

Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial

Dongsheng Yue, Wenxiang Wang, Hongxu Liu et al. · The Lancet Respiratory Medicine · 2024 · 110 citations

Medicine, Oncology, Surgery +16

Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients

Dongsheng Yue, Weiran Liu, Chen Chen et al. · Translational Lung Cancer Research · 2022 · 102 citations · Full text

Medicine, Molecular Medicine, Oncology +17

LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers

Chen Chen, Wei-Ran Liu, Bin Zhang et al. · Cancer Letters · 2020 · 98 citations

Medicine, Molecular Biology, Oncology +14

Hedgehog/Gli promotes epithelial-mesenchymal transition in lung squamous cell carcinomas

Dongsheng Yue, Hui Li, Juanjuan Che et al. · Journal of Experimental & Clinical Cancer Research · 2014 · 94 citations · Full text

Medicine, Cancer Biology, Oncology +17